Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product (BGY-1601-VT) as a First-line Monotherapy in Women With Acute Vaginal Infection: a Randomized, Double-blind, Placebo-controlled Study
Latest Information Update: 14 Jun 2024
At a glance
- Drugs BGY 1601 (Primary)
- Indications Bacterial vaginosis; Vulvovaginal candidiasis
- Focus Therapeutic Use
- Acronyms ELINA
- Sponsors Nexbiome Therapeutics
Most Recent Events
- 14 Jun 2024 New trial record